Wave Life Sciences (NASDAQ: WVE) posts new corporate investor presentation

Rhea-AI Filing Summary

Wave Life Sciences Ltd. furnished an updated corporate presentation to the investment community. The presentation, dated September 24, 2025, provides updates and summaries of the company’s business and is available in the “For Investors & Media” section of its website and as Exhibit 99.1. The information is furnished under a regulation fair disclosure item and is not considered filed for liability purposes under the Exchange Act, unless specifically incorporated into another filing.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001631574 0001631574 2025-09-24 2025-09-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 24, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower
Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 7.01 Regulation FD Disclosure.

From time to time, Wave Life Sciences Ltd. (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On September 24, 2025, the Company updated its corporate presentation, which is available on the “For Investors & Media” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 7.01 is furnished and not filed:

Exhibit No.		Description
99.1		Corporate Presentation of Wave Life Sciences Ltd. dated September 24, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Kyle Moran
		Kyle Moran
		Chief Financial Officer

Date: September 24, 2025

FAQ

What did Wave Life Sciences Ltd. (WVE) disclose in this 8-K filing?

Wave Life Sciences Ltd. furnished an updated corporate presentation, dated September 24, 2025, providing business updates and summaries to the investment community as Exhibit 99.1.

Where can investors find Wave Life Sciences Ltd.’s updated corporate presentation?

The updated corporate presentation is available on the company’s website in the “For Investors & Media” section and is also furnished as Exhibit 99.1 to this report.

Is the Wave Life Sciences Ltd. presentation considered filed with the SEC?

No. The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act unless specifically incorporated by reference in another filing.

What is the exhibit included with this Wave Life Sciences Ltd. 8-K?

The filing includes Exhibit 99.1, the corporate presentation of Wave Life Sciences Ltd. dated September 24, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Which Exchange Act item does this Wave Life Sciences Ltd. 8-K relate to?

The disclosure is made under Item 7.01, which covers Regulation FD (Fair Disclosure) information related to communications with the investment community.

Who signed this Wave Life Sciences Ltd. 8-K filing?

The report was signed on behalf of Wave Life Sciences Ltd. by Kyle Moran, Chief Financial Officer.